CN100358527C - 用于减少细胞毒性化疗的毒副作用的含有氨基酸与核黄素的制剂 - Google Patents

用于减少细胞毒性化疗的毒副作用的含有氨基酸与核黄素的制剂 Download PDF

Info

Publication number
CN100358527C
CN100358527C CNB028236068A CN02823606A CN100358527C CN 100358527 C CN100358527 C CN 100358527C CN B028236068 A CNB028236068 A CN B028236068A CN 02823606 A CN02823606 A CN 02823606A CN 100358527 C CN100358527 C CN 100358527C
Authority
CN
China
Prior art keywords
concentration
riboflavin
glycine
valine
threonine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028236068A
Other languages
English (en)
Chinese (zh)
Other versions
CN1596109A (zh
Inventor
斯坦尼斯劳R·伯辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1596109A publication Critical patent/CN1596109A/zh
Application granted granted Critical
Publication of CN100358527C publication Critical patent/CN100358527C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028236068A 2001-11-27 2002-11-21 用于减少细胞毒性化疗的毒副作用的含有氨基酸与核黄素的制剂 Expired - Fee Related CN100358527C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US09/995,010 2001-11-27

Publications (2)

Publication Number Publication Date
CN1596109A CN1596109A (zh) 2005-03-16
CN100358527C true CN100358527C (zh) 2008-01-02

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028236068A Expired - Fee Related CN100358527C (zh) 2001-11-27 2002-11-21 用于减少细胞毒性化疗的毒副作用的含有氨基酸与核黄素的制剂

Country Status (21)

Country Link
US (2) US20030105104A1 (enExample)
EP (1) EP1450781B1 (enExample)
JP (1) JP4614660B2 (enExample)
KR (1) KR100953483B1 (enExample)
CN (1) CN100358527C (enExample)
AT (1) ATE330595T1 (enExample)
BR (1) BR0214430A (enExample)
CA (1) CA2468133C (enExample)
DE (1) DE60212693T2 (enExample)
EA (1) EA009516B1 (enExample)
HU (1) HU230986B1 (enExample)
IL (2) IL162141A0 (enExample)
MX (1) MXPA04004994A (enExample)
NO (1) NO332858B1 (enExample)
NZ (1) NZ532833A (enExample)
PL (1) PL353656A1 (enExample)
RO (1) RO121173B1 (enExample)
SI (1) SI21542A (enExample)
UA (1) UA78977C2 (enExample)
WO (1) WO2003045372A1 (enExample)
ZA (1) ZA200404115B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100413866C (zh) * 2002-08-02 2008-08-27 中国人民解放军军事医学科学院放射医学研究所 核黄素衍生物及其制备方法与应用
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
RU2240788C1 (ru) * 2003-09-09 2004-11-27 Воронежская государственная медицинская академия им. Н.Н. Бурденко Детоксикационное средство
WO2006056794A1 (en) 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2008008084A2 (en) * 2005-09-19 2008-01-17 Cdm Optics, Inc. Task-based imaging systems
WO2007119378A1 (ja) * 2006-03-15 2007-10-25 Suntory Limited リボフラビンとセサミン類とを含有する組成物
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
WO2008105384A1 (ja) * 2007-02-26 2008-09-04 Kyowa Hakko Bio Co., Ltd. シトルリン含有錠剤
US9609884B2 (en) 2007-03-15 2017-04-04 Suntory Holdings Limited Anti-fatigue agent
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP3011843A1 (en) 2008-09-19 2016-04-27 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
CN108420827A (zh) 2010-07-22 2018-08-21 雷文制药有限公司 包含磁偶极子稳定化溶液的组合物及其用途
MX2013003282A (es) * 2010-09-24 2013-05-09 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
CN103429234B (zh) 2010-12-10 2016-10-05 布罗迪健康科学有限公司 茉莉酮酸酯治疗膀胱功能障碍的用途
TWI551288B (zh) * 2011-02-17 2016-10-01 Ea Pharma Co Ltd Antimicrobial activity enhancer for chemotherapeutic agents
US20130011488A1 (en) * 2011-07-07 2013-01-10 Nezami Md Mohammad Systems, Methods, and Formulations for Treating Cancer
CN110522744B (zh) 2013-03-11 2023-04-07 佛罗里达大学研究基金会有限公司 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法
PL3065751T3 (pl) * 2013-11-08 2020-07-13 Legacy Healthcare Ltd Sposób leczenia raka i chorób współistniejących
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
IL270413B (en) 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes of making l-ornithine phenylacetate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
US5546927A (en) * 1993-04-29 1996-08-20 Eurofours S.A. Oven door
US6013278A (en) * 1996-05-14 2000-01-11 Burzynski Research Institute Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
ES2033667T3 (es) * 1985-10-23 1993-04-01 Dr. Kurt Mulli Nachf. Gmbh & Co. Kg Composicion farmaceutica que contiene fracciones de extractos de timo.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
EP0421309B2 (en) * 1989-10-02 2001-08-16 Novartis Nutrition AG Protein hydrolysates
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2173109T3 (es) * 1992-12-23 2002-10-16 Abbott Lab Alimentos de unso medico destinados parael sostenimiento nutricional de recien nacidos/de bebes que padecen enfermedades metabolicas.
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
DE69910746T2 (de) 1999-06-26 2004-06-17 B. Braun Melsungen Ag Wässrige Lösung für parenterale Nahrung
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
US5546927A (en) * 1993-04-29 1996-08-20 Eurofours S.A. Oven door
US6013278A (en) * 1996-05-14 2000-01-11 Burzynski Research Institute Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
WO2003045372A1 (en) 2003-06-05
CN1596109A (zh) 2005-03-16
KR20040065565A (ko) 2004-07-22
EA009516B1 (ru) 2008-02-28
BR0214430A (pt) 2004-11-03
IL162141A (en) 2009-05-04
SI21542A (sl) 2005-02-28
ZA200404115B (en) 2005-11-30
HUP0402240A2 (hu) 2005-02-28
EP1450781B1 (en) 2006-06-21
DE60212693T2 (de) 2007-07-05
DE60212693D1 (de) 2006-08-03
EA200400737A1 (ru) 2004-12-30
MXPA04004994A (es) 2005-04-08
US20030105104A1 (en) 2003-06-05
NO332858B1 (no) 2013-01-21
KR100953483B1 (ko) 2010-04-16
CA2468133C (en) 2011-02-22
US20050182064A1 (en) 2005-08-18
PL353656A1 (en) 2003-06-02
NZ532833A (en) 2006-12-22
HUP0402240A3 (en) 2012-09-28
JP2005518361A (ja) 2005-06-23
HU230986B1 (hu) 2019-08-28
JP4614660B2 (ja) 2011-01-19
CA2468133A1 (en) 2003-06-05
RO121173B1 (ro) 2007-01-30
ATE330595T1 (de) 2006-07-15
UA78977C2 (en) 2007-05-10
NO20042364L (no) 2004-06-07
IL162141A0 (en) 2005-11-20
US7427619B2 (en) 2008-09-23
AU2002352843A1 (en) 2003-06-10
EP1450781A1 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
CN100358527C (zh) 用于减少细胞毒性化疗的毒副作用的含有氨基酸与核黄素的制剂
Harkness The history of enteral nutrition therapy: from raw eggs and nasal tubes to purified amino acids and early postoperative jejunal delivery
CN101061860B (zh) 富含亮氨酸的营养组合物
US8778410B2 (en) Oral or enteral composition useful for recovery of physical functions
Anderson et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation
CN101212961A (zh) 羟甲基丁酸盐组合物及其应用
TWI429405B (zh) 用於靜脈營養療法的小兒胺基酸溶液
AUSTGEN et al. The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues
US5888553A (en) Non-steroidal anabolic composition
JP2005529980A (ja) 代謝ストレスを受けている哺乳動物における異化を治療または予防し、同化を促進する方法及び組成物
JP2007517026A (ja) パントテン酸又はその誘導体を含む組成物、及び食欲を増進するためのその使用
JP2010254619A (ja) 栄養剤、消化器剤
CN105407744A (zh) 含有β-羟基-β-甲基丁酸的低卡路里婴儿配方
CN109090580A (zh) 一种用于肿瘤患者的特定全营养配方食品及其制备方法
CN108391811A (zh) 一种肿瘤全营养配方食品及其应用
CN106036387A (zh) 超级藜麦儿童生长营养包
RU2335927C2 (ru) Обогащенные лейцином питательные композиции
AU2002352843B2 (en) Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
CN106822867A (zh) 肝病临床营养剂及其应用
McNeal et al. The role of arginine for treating obese youth
JPH06172191A (ja) ブドウ糖加電解質輸液
HK1194671A (en) Nutritional composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080102

Termination date: 20201121